[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640750":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":37,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":10,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":10,"overallStatus":58,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"European Institute of Oncology","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Breast cancer survivors",null,"Female breast cancer survivors",{"label":13,"type":10,"description":14,"interventionNames":10},"Non-cancer control","Female without any history of cancer",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Gabriella Pravettoni, MD, PhD","CONTACT","+39 0257489731","gabriella.pravettoni@ieo.it",[22],{"facility":5,"status":10,"city":23,"state":10,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Milan","20435","Italy","IT",{"type":28,"coordinates":29},"Point",[30,31],12.59836,42.78235,{"lat":31,"lon":30},[34,35],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},{"name":17,"role":36,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100640750","cognitive-impairment-assessment-in-breast-cancer-survivors-100640750",false,"NCT07582770","Cognitive Impairment Assessment in Breast Cancer Survivors","Validation of Neuropsychological Tests for the Assessment of Cognitive Impairment in Breast Cancer Survivors","Inclusion Criteria:\n\n* Age between 18 and 65 years old\n* Patient with a previous documented diagnosis of non-metastatic breast cancer (only for breast cancer survivor gruop)\n* Patient has completed chemotherapy for at least 6 months and for a maximum of 36 months if planned (only for breast cancer survivor gruop)\n* Understanding of the Italian language and ability to give informed consent\n\nExclusion Criteria:\n\n* Presence of brain metastases or history of brain radiation therapy (only for breast cancer survivor gruop)\n* Patient with previous diagnosis of other malignant tumors in addition to breast cancer (only for breast cancer survivor gruop)\n* Patient with a previous diagnosis of malignant carcinomas (only for control gruop)\n* Patient with a history of brain damage with unresolved neurological consequences\n* Patient with previous or current serious neurological pathologies\n* Patient with severe psychiatric conditions\n* Patient with systemic pathologies that could interfere with cognitive abilities\n* Patient taking medications that have a strong cognitive impact and that have not been stabilized for at least 4 weeks prior to enrollment\n* Patient with visual or hearing impairments that are not properly corrected\n* Patient with any disability that might compromise the validity of cognitive tests",true,"FEMALE","18 Years","65 Years",{"count":51,"type":52},200,"ESTIMATED","OBSERVATIONAL","This study is a monocentric, observational, cross-sectional study with a case-control design, aimed at evaluating the construct validity, discriminative ability, and diagnostic accuracy of a second-level neuropsychological test battery for the detection of cancer-related cognitive impairment in breast cancer survivors.",[56,57],"Cancer Related Cognitive Impairment","Breast Cancer Survivors","NOT_YET_RECRUITING","2026-05-06",{"date":61,"type":62},"2026-05-13","ACTUAL",{"date":64,"type":52},"2026-05",{"date":66,"type":52},"2030-04",{"name":5,"class":6},1]